AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hair sample collection
Description: Hair sample collection will be performed. Hair mineral analysis will be performed.
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample collection
Description: Urine sample collection will be performed. Urine mineral analysis will be performed.
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition analysis
Description: Body composition analysis with the use of electric bioimpedance will be performed.
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
Study NCT04451616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure, pulse and blood oxygen saturation measurement
Description: Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
Study NCT02449317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioimpedance guided
Description: bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water > 0.4 : 1 ml/kg/hr
Study NCT02449317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard hydration
Description: standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
Study NCT03585153 — intervention group
Intervention type: OTHER
Intervention: Non-contrast magnetic resonance imaging
Description: subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
Study NCT04539119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
Study NCT04539119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
Study NCT04470219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive support by RemindMe
Study NCT02421900 — intervention group
Intervention type: OTHER
Intervention: radio-frequency catheter ablation of atrial fibrillation
Description: radio-frequency catheter ablation of atrial fibrillation
Study NCT01701193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Alanyl/L-Glutamine
Description: Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
Study NCT01701193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo
Study NCT04417192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
Study NCT04417192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study NCT01936181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade (infliximab)
Study NCT01936181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB2 (proposed biosimilar to infliximab)
Study NCT03308136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
Description: 1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
Study NCT03308136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
Description: 2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.
Study NCT03308136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: 1% Lidocaine
Study NCT03308136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine
Description: 1% Lidocaine
Study NCT02763982 — intervention group
Intervention type: OTHER
Intervention: Physical evaluation
Study NCT03070340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast Magnetic Resonance Imaging (MRI)
Description: All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
Study NCT03070340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography (CEDM)
Description: All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
Study NCT00868725 — intervention group
Intervention type: OTHER
Intervention: no intervention, observation only
Description: Oral cavity will be imaged by a thermal camera.
Study NCT03005223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156
Study NCT03005223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20163
Study NCT02811016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200
Description: 200 µg inhaled at 7:00 a.m. and 7 p.m.
Study NCT02811016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 800
Description: 800 µg inhaled at 7:00 a.m. and 7 p.m.
Study NCT02811016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation at 7:00 a.m. and 7 p.m.
Study NCT03405272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
Description: Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
Study NCT04232098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat to ankle
Description: Heat administered via hot water to ankle level
Study NCT04232098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat to calf
Description: Heat administered via hot water to calf level
Study NCT04977518 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04041752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLID
Description: condition with a classical meal served using solid food items
Study NCT04041752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIQUID_P
Description: condition with a liquid meal served using a powder solution
Study NCT04041752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIQUID_L
Description: condition with a pre-prepared meal served using a liquid solution.
Study NCT02459249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
Study NCT02459249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator (Treatment of Mexican Health Minister)
Description: General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
Study NCT02596022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session
Study NCT02596022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581a
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session
Study NCT02596022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581b
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session
Study NCT02596022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session
Study NCT00642629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STA 5326 mesylate
Description: STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Study NCT00642629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Study NCT02070120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
Study NCT02070120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Management
Description: Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
Study NCT01200030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electrical stimulation with exercises
Description: electrical stimulation with exercises
Study NCT01200030 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo stimulation with exercises
Description: placebo stimulation with exercises
Study NCT00385853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: Twice daily for each 28-day cycle
Study NCT00385853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Daily for each 28-day cycle
Study NCT00385853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: For 7 weeks beginning on day 5 of the first treatment cycle
Study NCT03459703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
Study NCT03459703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Schedule
Description: Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
Study NCT03459703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Weight Loss Program
Description: A structured weight loss program with physical activity recommendations and dietary counseling.
Study NCT03459703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Weight Loss Program
Description: A structured weight loss program with physical activity recommendations and dietary counseling.
Study NCT02632786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Study NCT02632786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Bag
Study NCT00237484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
Description: 1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks
Study NCT00237484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
Description: 1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks
Study NCT03759613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.
Study NCT03759613 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.
Study NCT03759613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.
Study NCT02461875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
Study NCT02461875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist rescue & cabergoline
Description: when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluouracil
Description: Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
Study NCT01588990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
Study NCT00595829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL019
Description: XL019 capsules administered orally
Study NCT04184362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation
Description: Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
Study NCT04184362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation
Description: Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
Study NCT01444729 — intervention group
Intervention type: DRUG
Intervention: Xiapex
Description: Xiapex administration will follow SMPC
Study NCT01444729 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: Non-pharmacological treatment
Study NCT03828110 — intervention group
Intervention type: DEVICE
Intervention: Robotic Assisted Gait Training (Lokomat)
Description: The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
Study NCT03828110 — intervention group
Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
Study NCT00995046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII
Description: 6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
Study NCT00995046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: 1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
Study NCT00784238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
Study NCT04283344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KY Ticket to Healthy Food Benefits
Description: Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
Study NCT04439006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04439006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02653040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic lighting
Description: Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity